LONDON, May 2 (Reuters) - Novo Nordisk posted
on Thursday first-quarter operating profit above analyst
forecasts, as the Danish drugmaker races to boost output of its
hugely popular weight-loss drug Wegovy and fend off competition
from Eli Lilly ( LLY ).